Subscribe

News
Video
Podcasts
Journals
Conferences
Events
Resources
CE
About AJMC
Subscribe

Spotlight -

Free In-Person Regional Events Focused on Oncology and Population Health

Opinion|Videos|March 11, 2025

Optimizing Treatment Sequencing in Advanced Colorectal Cancer

Author(s)Scott Soefje, PharmD, MBA, BCOP, FCCP, FHOPA , Melody Chang, RPh, MBA, BCOP, Nicholas Bouchard, PharmD

Experts discuss additional factors considered when determining the most effective sequence of therapies for metastatic colorectal cancer, including fruquintinib, regorafenib, and trifluridine + tipiracil ± bevacizumab, and explore the further research needed to understand optimal sequencing of these treatments better.

Episodes in this series

EP. 1 Treatment Options in mCRC: A Clinical Overview

EP. 1 Treatment Options in mCRC: A Clinical Overview

EP. 2 Comparing Safety Profiles: Making Informed Treatment Decisions in mCRC

EP. 2 Comparing Safety Profiles: Making Informed Treatment Decisions in mCRC

EP. 3 Quality of Life and Patient Outcomes in mCRC Treatment

EP. 3 Quality of Life and Patient Outcomes in mCRC Treatment

EP. 4 Optimizing Treatment Sequencing in Advanced Colorectal Cancer

EP. 4 Optimizing Treatment Sequencing in Advanced Colorectal Cancer

EP. 5 The Patient Journey: Mapping the Pharmacist’s Role in mCRC Management

EP. 5 The Patient Journey: Mapping the Pharmacist’s Role in mCRC Management

EP. 6 Evolution of Oncology Pharmacy Practice in mCRC

EP. 6 Evolution of Oncology Pharmacy Practice in mCRC

EP. 7 Pharmacist-Led Strategies for Adverse Event Management in mCRC

EP. 7 Pharmacist-Led Strategies for Adverse Event Management in mCRC

EP. 8 Navigating Cost Considerations in Treatment Selection of mCRC Agents

EP. 8 Navigating Cost Considerations in Treatment Selection of mCRC Agents

EP. 9 Best Practices for Overcoming mCRC Prior Authorization Barriers

EP. 9 Best Practices for Overcoming mCRC Prior Authorization Barriers

EP. 10 Building Better Collaboration: Reducing Care Delays in Managing mCRC

EP. 10 Building Better Collaboration: Reducing Care Delays in Managing mCRC

Video content above is prompted by the following:

What additional factors do you consider when determining the most effective sequence of these therapies (fruquintinib, regorafenib, trifluridine + tipiracil ± bevacizumab)?
What further research is needed to understand optimal sequencing of these therapies better?

Newsletter

Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.

Related Content

Obesity, Insulin Resistance, and the Silent Progression of MASH: A Hepatologist's Perspective

ByMazen Noureddin, MD, MHSc

July 24th 2026

Advanced Treatments, Biologic Cycling, and Head-to-Head Data in Atopic Dermatitis

ByAngela J. Lamb, MD

July 24th 2026

Transplants, Decompensation, and the True Cost of Untreated MASH

ByNadege Gunn, MD

July 24th 2026

The Road Ahead: Personalized Therapy, Combination Approaches, and Key Takeaways in Extrapulmonary Neuroendocrine Carcinoma

ByRyan Haumschild, PharmD, MBA,William K. Oh, MD,Aman Chauhan, MD,Namrata Vijayvergia, MD,Sandy Kotiah, MD

July 20th 2026

SYNCHRONIZE-1 Through a Hepatologist's Lens: Liver Fat Reduction, Visceral Fat, and What Comes Next

ByNadege Gunn, MD

July 17th 2026

Trending on AJMC

Judge Denies Preliminary Injunction in Medicaid Work Requirements Case

AHRQ Grant Freeze Halts Patient Safety Research Nationwide

Contributor: Artificial Intelligence Grows Across Health Care, Led by Administrative Processes

Can Oral Semaglutide Reduce Heavy Drinking in Alcohol Use Disorder?

Wildfire Smoke Raises Asthma Risks as Fires Worsen Air Quality Across North America